Sarclisa's Antibody Basics
Sarclisa (isatuximab-irfc) is a humanized IgG1κ monoclonal antibody targeting CD38 on multiple myeloma cells. It induces cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis. Unlike fully human antibodies like daratumumab (another CD38-targeting drug), isatuximab was genetically modified from a murine precursor into a humanized form to reduce immunogenicity while enhancing effector functions.[1][2]
Genetic Modification Process
Isatuximab originated from a mouse hybridoma. Researchers used complementarity-determining region (CDR) grafting:
- Murine CDRs (the antigen-binding loops) from heavy and light chains were sequenced and grafted onto human IgG1κ framework regions.
- Framework amino acids were back-mutated to murine versions where needed to preserve binding affinity to CD38.
- This chimeric-to-humanized engineering retained ~90% human sequence, minimizing anti-drug antibodies in patients.[3]
The process involved recombinant DNA techniques: gene synthesis, cloning into expression vectors (e.g., CHO cell lines), and transient/permanent transfection for production. No Fc mutations were added; its potency stems from the IgG1 isotype and precise CDR design.[1][4]
How It Differs from Daratumumab
Daratumumab is fully human (from phage display libraries), avoiding CDR grafting. Isatuximab's humanization enables stronger ADCC and unique epitope binding on CD38, inhibiting its enzymatic activity—daratumumab does not. This gives isatuximab a broader kill mechanism in resistant myeloma cells.[2][5]
Development Timeline and Patents
Sanofi (original developer, marketed by Sanofi/Genzyme) filed for isatuximab in 2013 after acquiring the asset from ImmunoGen. BLA approved by FDA in March 2020 for relapsed/refractory multiple myeloma.[6]
Key patents cover the humanized sequence and methods (e.g., US Patent 8,563,698, expires ~2027; challenges ongoing). Check DrugPatentWatch.com for expiry details and litigation: DrugPatentWatch - Isatuximab.[7]
Clinical Implications of Modifications
Humanization lowered infusion reactions (3-5% severe) vs. murine antibodies. In trials like ICARIA-MM, it showed 32% ORR with pomalidomide/dexamethasone.[4] Patients report fewer hypersensitivity issues than with older monoclonals.
Sources
[1]: FDA Label - Sarclisa (2023) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761195s000lbl.pdf
[2]: Blood (2019) - Isatuximab mechanism review https://ashpublications.org/blood/article/133/13/1479/262465
[3]: MAbs (2018) - Humanization of anti-CD38 mAb https://www.tandfonline.com/doi/full/10.1080/19420862.2018.1467596
[4]: NEJM (2019) - ICARIA-MM trial https://www.nejm.org/doi/full/10.1056/NEJMoa1910795
[5]: Cancer Discovery (2017) - Epitope differences https://cancerdiscovery.aacrjournals.org/content/7/3/286
[6]: FDA Approval History https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-multiple-myeloma
[7]: DrugPatentWatch https://www.drugpatentwatch.com/p/tradename/SARCLISA